

Appendix Table F59. Evidence of dose response association in clinical outcomes after solifenacin 5 vs.10mg/day (pooled individual patient data from RCTs)

Outcome	Reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Continence	Staskin, 2006 ³⁹	611	0.76 (0.58; 0.98)	-0.10 (-0.18; -0.01)	-10 (-71; -5)	-99 (-184; -14)
Continence	Cardozo, 2006 ²⁵⁰	1092	0.98 (0.86; 1.11)			
Discontinued treatment due to adverse effects	Cardozo, 2006 ²⁵⁰	1092	0.68 (0.38; 1.21)			
Discontinued treatment due to adverse effects	Staskin, 2006 ³⁹	611	0.37 (0.13; 1.02)	-0.04 (-0.08; -0.01)	-23 (-103; -13)	-43 (-77; -10)
Dry mouth	Cardozo, 2006 ²⁵⁰	1092	0.38 (0.28; 0.53)	-0.18 (-0.23; -0.13)	-6 (-8; -4)	-179 (-226; -132)
Dry mouth	Staskin, 2006 ³⁹	1811	0.40 (0.31; 0.51)	-0.17 (-0.20; -0.13)	-6 (-8; -5)	-167 (-202; -131)
Mild dry mouth	Cardozo, 2006 ²⁵⁰	1147	0.47 (0.32; 0.69)	-0.10 (-0.14; -0.06)	-10 (-17; -7)	-99 (-140; -58)
Moderate dry mouth	Cardozo, 2006 ²⁵⁰	1147	0.25 (0.12; 0.55)	-0.06 (-0.09; -0.04)	-16 (-26; -11)	-63 (-87; -38)
Severe dry mouth	Cardozo, 2006 ²⁵⁰	1147	0.08 (0.00; 1.26)	-0.02 (-0.03; -0.01)	-51 (-111; -33)	-20 (-30; -9)
Blurred vision	Cardozo, 2006 ²⁵⁰	1092	0.89 (0.48; 1.66)			
Blurred vision	Staskin, 2006 ³⁹	1811	0.80 (0.49; 1.28)			
Mild blurred vision	Cardozo, 2006 ²⁵⁰	1147	0.96 (0.47; 1.98)			
Moderate blurred vision	Cardozo, 2006 ²⁵⁰	1147	0.63 (0.13; 2.94)			
Severe blurred vision	Cardozo, 2006 ²⁵⁰	1147	0.63 (0.07; 5.59)			
Constipation	Cardozo, 2006 ²⁵⁰	1092	0.45 (0.29; 0.72)	-0.08 (-0.11; -0.04)	-13 (-25; -9)	-76 (-113; -40)
Constipation	Staskin, 2006 ³⁹	1811	0.40 (0.28; 0.58)	-0.08 (-0.11; -0.05)	-12 (-19; -9)	-80 (-107; -54)
Mild constipation	Cardozo, 2006 ²⁵⁰	1147	0.74 (0.42; 1.29)	-0.02 (-0.04; 0.01)		
Moderate constipation	Cardozo, 2006 ²⁵⁰	1147	0.24 (0.10; 0.59)	-0.05 (-0.07; -0.03)	-20 (-36; -14)	-49 (-71; -28)
Severe constipation	Cardozo, 2006 ²⁵⁰	1147	0.23 (0.03; 1.76)	-0.01 (-0.02; 0.00)		